Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
{"title":"Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","authors":"","doi":"10.1016/s1470-2045(24)00647-8","DOIUrl":null,"url":null,"abstract":"In April, 2021, <em>The Lancet Oncology</em> published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in <em>PIK3CA</em>-mutated, hormone receptor-positive advanced breast cancer.<span><span><sup>1</sup></span></span>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00647-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In April, 2021, The Lancet Oncology published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer.1
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
